Cadrenal Therapeutics Reports Positive Ph 2 Results for CAD-1005
24 Feb 2026 //
GLOBENEWSWIRE
Cadrenal Therapeutics Showcases VLX-1005 At J.P. Morgan Conf
12 Jan 2026 //
GLOBENEWSWIRE
Cadrenal Therapeutics Acquires Phase 2 12-LOX Inhibitor VLX-1005
12 Dec 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support